弥漫大B细胞淋巴瘤患者血浆MGMT基因甲基化与化疗疗效关系

目的检测弥漫大B细胞淋巴瘤（DLBCL）患者外周血血浆中06．甲基鸟嘌呤．DNA甲基转移酶（O6-methylgua-nine-DNAmethyltransferase，MGMT）基因的甲基化状态，探讨MGMT基因甲基化与含烷化剂方案治疗DLBCL疗效的关系。方法利用巢式甲基化特异性聚合酶链反应法检测CHOP方案治疗前后DLBCL患者外周血血浆MGMT基因的甲基化状态。结果30例DLBCL患者血浆MGMT基因甲基化率为63．3％（19／30），血浆MGMT基因甲基化者化疗有效率为100．O％（19／19），非甲基化者化疗有效率为72．7％（8／11），两组化疗有效率差异有统计学意义（P=0．041）。血浆MGMT基因甲基化者化疗后耐药发生率为10．5％（2／19），非甲基化者耐药发生率为54．5％（6／11），两组化疗耐药率差异有统计学意义（P=0．028）。结论外周血血浆中MGMT基因甲基化可能是预示DLBCL使用含烷化剂方案化疗疗效和耐药的指标。

Relationship between methylation of MGMT gene in plasma of patients with diffuse large B-cell lymphoma and efficacy of chemotherapy

Objective To detect the methylation of gene O6-methylguanine DNA methyhransferase （MGMT） in peripheral plasma of patients with diffuse large B-cell lymphoma （DLBCL） ,and to evaluate the relationship between methylation of MGMT and efficacy of chemotherapy on DLBCL Methods Before and after chemotherapy, nested-methylation specific PCR （nMSP） was performed for detecting methylation of MGMT in plasma from DLBCL patients who were treated with CHOP. Results Methylation of MGMT was found in 63.3% （19/30） of patients with DLBCL The response rates were 100% （ 19/19 ） in patients with methylation of MGMT and 72. 7% （8/11 ） in patients with non-methylation of MGMT, and the difference between two groups was statistically significant （ P = 0. 041 ）. The ratios of resistance to chemotherapy were 10. 5% （ 2/19 ） in pa- tients with methylation of MGMT and 54. 5% （6/11） in patients with non-methylation of MGMT, and the difference between two groups was statistically significant （ P = 0. 028 ）. Conclusion Methylation of MGMT in peripheral plasma of DLBCL patients might be a biomarker of response or resistant to chemotherapy with alkylating agents based regimens.